BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24090491)

  • 1. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.
    Molino NM; Anderson AK; Nelson EL; Wang SW
    ACS Nano; 2013 Nov; 7(11):9743-52. PubMed ID: 24090491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
    Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
    Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
    Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
    J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
    Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
    Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.
    Reinis M; Stepanek I; Simova J; Bieblova J; Pribylova H; Indrova M; Bubenik J
    Int J Oncol; 2010 Mar; 36(3):545-51. PubMed ID: 20126973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
    Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
    Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development.
    Han JA; Kang YJ; Shin C; Ra JS; Shin HH; Hong SY; Do Y; Kang S
    Nanomedicine; 2014 Apr; 10(3):561-9. PubMed ID: 24262997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
    Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
    J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
    Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
    J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octaarginine-modified liposomes enhance cross-presentation by promoting the C-terminal trimming of antigen peptide.
    Nakamura T; Ono K; Suzuki Y; Moriguchi R; Kogure K; Harashima H
    Mol Pharm; 2014 Aug; 11(8):2787-95. PubMed ID: 24901376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
    Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
    J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choose your models wisely: how different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro.
    Dewitte H; Verbeke R; Breckpot K; Vandenbroucke RE; Libert C; De Smedt SC; Lentacker I
    J Control Release; 2014 Dec; 195():138-46. PubMed ID: 24960224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.
    Fessenden TB; Stopfer LE; Chatterjee F; Zulueta J; Mesfin J; Cordero Dumit T; Reijers I; Hoefsmit EP; Blank C; White F; Spranger S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35820727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
    Kamphorst AO; Guermonprez P; Dudziak D; Nussenzweig MC
    J Immunol; 2010 Sep; 185(6):3426-35. PubMed ID: 20729332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses.
    Walter F; Winter E; Rahn S; Heidland J; Meier S; Struzek AM; Lettau M; Philipp LM; Beckinger S; Otto L; Möller JL; Helm O; Wesch D; Scherließ R; Sebens S
    PLoS One; 2020; 15(9):e0239369. PubMed ID: 32997691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
    Ikeuchi N; Futami J; Hosoi A; Noji S; Kurachi M; Ueha S; Fujii S; Yamada H; Matsushima K; Moriyasu F; Kakimi K
    Biochem Biophys Res Commun; 2010 Feb; 392(2):217-22. PubMed ID: 20067764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy.
    Bai S; Jiang H; Song Y; Zhu Y; Qin M; He C; Du G; Sun X
    J Control Release; 2022 Apr; 344():134-146. PubMed ID: 35217098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.